EvoSyn™ is a precise blend of caffeine, evodiamine and synephrine. This triad not only works synergistically together, but also beautifully compliments the ArecoLean™ blend.
Caffeine is one of the world’s most popular drugs. Caffeine acts in the brain by antagonising (blocking) adenosine A1 and A2A receptors (24, 25), thereby inhibiting the breakdown of Cyclic Adenosine Monophosphate (cAMP). Adenosine typically slows nerve cell activity, initiating a relaxed type of environment similar to the state experienced during sleep. By antagonising adenosine, this effect is in fact reversed and nerve cell activity is increased. This causes catecholamine release and central nervous stimulation that makes caffeine such a Godsend for those who find mornings difficult. Adenosine also inhibits dopamine release, thus inhibiting adenosine can help maintain dopamine signalling, which as explained earlier, is of the utmost importance.
While most users will testify that caffeine alone is a sound appetite suppressant, it appears that it has significant effects in potentiating the effect of other stimulants (26, 27). This stimulation can also aid performance by delaying fatigue and allowing one to maintain training intensity for a complete session (28). It can also assist strength training (29) and help improve endurance, making it a valuable compound to utilize for cardiovascular training which can further assist any fat loss endeavour (30).
Evodiamine is an alkaloid found in the Evodiae Fructus plant, and has been used for centuries in ancient Chinese medicine. Evodiamine exerts its fat loss effects in a similar manner to capsaicin, via agonizing the vanilloid receptor TRPV1, but does so without the risk of indigestion (31, 32.). TRPV1 is a receptor typically activated by heat or acidic conditions and is involved in pain regulation. Through activation of this receptor, Evodiamine simultaneously ramps up heat production, thereby promoting fat burning while also increasing heat loss via vasodilation.
As an added benefit, evodiamine has been shown to enhance the secretion of stimulatory neurotransmitters when induced by acetylcholine (33). This means that evodiamine works as another part of the synergistic formula with L-Huperzine-A and Arecoline to promote cAMP signalling in concert with caffeine.
The final ingredient in Adrenalean, Synephrine, is included as an added benefit for those with a big appetite. Synephrine is found naturally in the citrus tree Citrus Aurantium and when ingested acts an agonist of the alpha-1 adrenergic receptor (34, 35). While the rest of the Adrenalean formula will blunt hunger in most individuals, this activation of the alpha-1 receptor further suppresses the drive to eat in even the worst dieter (36). All variables considered, controlling food intake on your diet while using Adrenalean™ should not be a problem.
Many high calorie foods tastes good and eating is associated with a myriad of pleasurable physiological effects...face it, dieting is never “fun!” Then again, being fat, tired, and out of shape isn’t much fun either. Adrenalean is a highly effective stimulating fat burner that provides a smooth pharmaceutical grade energy that will last all day long. There’s no crash, no tremors, no shaking and NO APPETITE!
Using a complex formula of innovative ingredients, Adrenalean mimics the powerful effects of adrenaline and noradrenaline which destroy fat at an alarming rate and by boosting “feel good” chemicals in the brain, you’ll be sure to love every minute of it! Whether you want a daily fat burner to be used during your diet, a staple pre-workout stimulant to aid performance or something to enhance focus and get you through your school or work day, Adrenalean is your only choice.
1. Strickland SS, Veena GV, Houghton PJ, Stanford SC, Kurpad AV. Areca nut, energy metabolism and hunger in Asian men. Ann Hum Biol. 2003 Jan-Feb;30(1):26-52.
2. Laloux C, Derambure P, Jacquesson JM, Bordet R, Dest?e A, Monaca C. The effects of serotoninergic, noradrenergic, cholinergic and dopaminergic drugs on vigilance states in MPTP-treated mice. Brain Res. 2007 Aug 3;1161:79-87.
3. Kuş I, Sarsilmaz M, Oget?rk M, Yilmaz B, Keleştimur H, Oner H. Ultrastructural interrelationship between the pineal gland and the testis in the male rat. Arch Androl. 2000 Sep-Oct;45(2):119-24.
4. Saha I, Chatterji U, Chaudhuri-Sengupta S, Nag TC, Nag D, Banerjee S, Maiti BR. Ultrastructural and hormonal changes in the pineal-testicular axis following arecoline administration in rats. J Exp Zool Part A Ecol Genet Physiol. 2007 Apr 1;307(4):187-98.
5. Sabelli HC, Javaid JI. Phenylethylamine modulation of affect: therapeutic and diagnostic implications. J Neuropsychiatry Clin Neurosci. 1995 Winter;7(1):6-14.
6. Szabo A, Billett E, Turner J. Phenylethylamine, a possible link to the antidepressant effects of exercise? Br J Sports Med. 2001 Oct;35(5):342-3.
7. Paetsch PR, Greenshaw AJ. 2-Phenylethylamine-induced changes in catecholamine receptor density: implications for antidepressant drug action. Neurochem Res. 1993 Sep;18(9):1015-22.
8. Sabelli H, Fink P, Fawcett J, Tom C. Sustained antidepressant effect of PEA replacement. J Neuropsychiatry Clin Neurosci. 1996 Spring;8(2):168-71.
9. Barwell CJ, Basma AN, Lafi MA, Leake LD. Deamination of hordenine by monoamine oxidase and its action on vasa deferentia of the rat. J Pharm Pharmacol. 1989 Jun;41(6):421-3.
10. Ernsberger P, Koletsky RJ, Kilani A, Viswan G, Bedol D. Effects of weight cycling on urinary catecholamines: sympathoadrenal role in refeeding hypertension. J Hypertens. 1998 Dec;16(12 Pt 2):2001-5.
11. Hapke HJ, Strathmann W. [Pharmacological effects of hordenine] Dtsch Tierarztl Wochenschr. 1995 Jun;102(6):228-32.
12. Frank M, Weckman TJ, Wood T, Woods WE, Tai CL, Chang SL, Ewing A, Blake JW, Tobin T. Hordenine: pharmacology, pharmacokinetics and behavioural effects in the horse. Equine Vet J. 1990 Nov;22(6):437-41.
13. Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport. 1996 Dec 20;8(1):97-101.
14. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006 Jan;27(1):1-26.
15. Zhang HY, Tang XC. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci. 2006 Dec;27(12):619-25.
16. von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol. 2004 Aug;56(8):1039-44.
17. Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81. Epub 2004 Sep 8.
18. Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther. 2004 Jul-Aug;11(4):262-77.
19. Kang IH, Kim HJ, Oh H, Park YI, Dong MS. Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5. Mutat Res. 2004 Jan 12;545(1-2):37-47.
20. Singh A, Naidu PS, Kulkarni SK. Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition. Pharmacology. 2003 Jun;68(2):81-8.
21. Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother. 2005 Feb;17(1):86-95.
22. Yang ZG, Meng H, Zhang X, Li XD, Lv WL, Zhang Q. [Effect of quercetin on the acyclovir intestinal absorption]. Beijing Da Xue Xue Bao. 2004 Jun 18;36(3):309-12.
23. Nagai M, Conney AH, Zhu BT. Strong inhibitory effects of common tea catechins and bioflavonoids on the O-methylation of catechol estrogens catalyzed by human liver cytosolic catechol-O-methyltransferase. Drug Metab Dispos. 2004 May;32(5):497-504.
24. Justinova Z, Ferre S, Segal PN, Antoniou K, Solinas M, Pappas LA, Highkin JL, Hockemeyer J, Munzar P, Goldberg SR. Involvement of adenosine A1 and A2A receptors in the adenosinergic modulation of the discriminative-stimulus effects of cocaine and methamphetamine in rats. J Pharmacol Exp Ther. 2003 Dec;307(3):977-86.
25. Cauli O, Morelli M. Caffeine and the dopaminergic system. Behav Pharmacol. 2005 Mar;16(2):63-77.
26. Jessen A, Buemann B, Toubro S, Skovgaard IM, Astrup A. The appetite-suppressant effect of nicotine is enhanced by caffeine. Diabetes Obes Metab. 2005 Jul;7(4):327-33.
27. Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, Rhodes SL, Jungvig L, Gagne J. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003 Mar 26;289(12):1537-45. Epub 2003 Mar 10.
28. Davis JM, Zhao Z, Stock HS, Mehl KA, Buggy J, Hand GA. Central nervous system effects of caffeine and adenosine on fatigue. Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R399-404. Epub 2002 Oct 24.
29. Hespel P, Op't Eijnde B, Van Leemputte M. Opposite actions of caffeine and creatine on muscle relaxation time in humans. J Appl Physiol. 2002 Feb;92(2):513-8.
30. Cox GR, Desbrow B, Montgomery PG, Anderson ME, Bruce CR, Macrides TA, Martin DT, Moquin A, Roberts A, Hawley JA, Burke LM. Effect of different protocols of caffeine intake on metabolism and endurance performance. J Appl Physiol. 2002 Sep;93(3):990-9.
31. Kobayashi Y, Nakano Y, Kizaki M, Hoshikuma K, Yokoo Y, Kamiya T. Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med. 2001 Oct;67(7):628-33.
32. Pearce LV, Petukhov PA, Szabo T, Kedei N, Bizik F, Kozikowski AP, Blumberg PM. Evodiamine functions as an agonist for the vanilloid receptor TRPV1. Org Biomol Chem. 2004 Aug 21;2(16):2281-6.
33. Yoshizumi M, Houchi H, Ishimura Y, Hirose M, Kitagawa T, Tsuchiya K, Minakuchi K, Tamaki T. Effect of evodiamine on catecholamine secretion from bovine adrenal medulla. J Med Invest. 1997 Aug;44(1-2):79-82.
34. Hwa J, Perez DM. The unique nature of the serine interactions for alpha 1-adrenergic receptor agonist binding and activation. J Biol Chem. 1996 Mar 15;271(11):6322-7.
35. Brown CM, McGrath JC, Midgley JM, Muir AG, O'Brien JW, Thonoor CM, Williams CM, Wilson VG. Activities of octopamine and synephrine stereoisomers on alpha-adrenoceptors. Br J Pharmacol. 1988 Feb;93(2):417-29.
36. Wellman PJ. Norepinephrine and the control of food intake. Nutrition. 2000 Oct;16(10):837-42.